| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 106 | 2022 | 5097 | 6.110 |
Why?
|
| Medication Adherence | 15 | 2022 | 151 | 4.110 |
Why?
|
| Male | 128 | 2022 | 6754 | 3.140 |
Why?
|
| Neurocognitive Disorders | 11 | 2021 | 13 | 2.840 |
Why?
|
| Anti-Retroviral Agents | 16 | 2021 | 551 | 2.810 |
Why?
|
| Middle Aged | 85 | 2022 | 3601 | 2.810 |
Why?
|
| Humans | 161 | 2022 | 14537 | 2.800 |
Why?
|
| AIDS Dementia Complex | 14 | 2021 | 29 | 2.740 |
Why?
|
| Female | 122 | 2021 | 9103 | 2.500 |
Why?
|
| Antiretroviral Therapy, Highly Active | 29 | 2021 | 472 | 2.460 |
Why?
|
| Adult | 100 | 2021 | 5913 | 2.420 |
Why?
|
| Aged | 46 | 2022 | 1740 | 2.280 |
Why?
|
| Anti-HIV Agents | 30 | 2021 | 1324 | 2.270 |
Why?
|
| Cognition Disorders | 14 | 2018 | 36 | 2.180 |
Why?
|
| Text Messaging | 5 | 2020 | 25 | 2.110 |
Why?
|
| Frailty | 6 | 2021 | 15 | 2.050 |
Why?
|
| Cognitive Dysfunction | 4 | 2021 | 13 | 1.810 |
Why?
|
| Brain | 10 | 2021 | 53 | 1.810 |
Why?
|
| Neuropsychological Tests | 28 | 2022 | 55 | 1.780 |
Why?
|
| Bipolar Disorder | 5 | 2019 | 5 | 1.760 |
Why?
|
| Alzheimer Disease | 5 | 2021 | 30 | 1.690 |
Why?
|
| Aging | 12 | 2021 | 109 | 1.690 |
Why?
|
| Depression | 6 | 2022 | 121 | 1.690 |
Why?
|
| Hospitalization | 13 | 2021 | 418 | 1.640 |
Why?
|
| Pneumonia | 3 | 2021 | 131 | 1.520 |
Why?
|
| Inflammation | 3 | 2021 | 104 | 1.460 |
Why?
|
| HIV-1 | 12 | 2021 | 1260 | 1.330 |
Why?
|
| Mycobacterium tuberculosis | 6 | 2022 | 329 | 1.300 |
Why?
|
| Risk Factors | 33 | 2021 | 1475 | 1.210 |
Why?
|
| Infant | 34 | 2021 | 2244 | 1.160 |
Why?
|
| Reminder Systems | 2 | 2019 | 8 | 1.140 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2021 | 195 | 1.130 |
Why?
|
| Pneumococcal Vaccines | 10 | 2019 | 278 | 1.100 |
Why?
|
| Cross-Sectional Studies | 22 | 2022 | 1422 | 1.090 |
Why?
|
| Child, Preschool | 28 | 2021 | 1748 | 1.080 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 5 | 2022 | 226 | 1.060 |
Why?
|
| Pre-Exposure Prophylaxis | 5 | 2022 | 196 | 1.050 |
Why?
|
| Executive Function | 6 | 2020 | 23 | 1.050 |
Why?
|
| Methamphetamine | 7 | 2020 | 7 | 1.040 |
Why?
|
| Age Factors | 6 | 2020 | 370 | 1.010 |
Why?
|
| Pneumococcal Infections | 8 | 2019 | 299 | 1.010 |
Why?
|
| Telemedicine | 3 | 2020 | 25 | 0.970 |
Why?
|
| Quality of Life | 6 | 2021 | 177 | 0.910 |
Why?
|
| HIV Seropositivity | 8 | 2020 | 265 | 0.900 |
Why?
|
| Neurodegenerative Diseases | 3 | 2018 | 19 | 0.900 |
Why?
|
| Cohort Studies | 24 | 2021 | 967 | 0.880 |
Why?
|
| Logistic Models | 16 | 2021 | 254 | 0.880 |
Why?
|
| Comorbidity | 13 | 2021 | 188 | 0.880 |
Why?
|
| Coinfection | 7 | 2021 | 276 | 0.870 |
Why?
|
| Viral Load | 15 | 2020 | 819 | 0.870 |
Why?
|
| Aged, 80 and over | 10 | 2022 | 468 | 0.830 |
Why?
|
| Adolescent | 36 | 2021 | 2985 | 0.820 |
Why?
|
| Amphetamine-Related Disorders | 4 | 2020 | 5 | 0.810 |
Why?
|
| HIV Seronegativity | 3 | 2020 | 52 | 0.810 |
Why?
|
| Case-Control Studies | 16 | 2022 | 480 | 0.780 |
Why?
|
| Longitudinal Studies | 9 | 2021 | 435 | 0.730 |
Why?
|
| CD4 Lymphocyte Count | 21 | 2021 | 656 | 0.710 |
Why?
|
| Streptococcus pneumoniae | 6 | 2017 | 336 | 0.700 |
Why?
|
| Disease Management | 2 | 2019 | 74 | 0.680 |
Why?
|
| Health Services Accessibility | 3 | 2019 | 280 | 0.670 |
Why?
|
| Prevalence | 16 | 2020 | 1192 | 0.670 |
Why?
|
| Substance-Related Disorders | 8 | 2019 | 51 | 0.660 |
Why?
|
| Population Groups | 1 | 2019 | 9 | 0.660 |
Why?
|
| Primary Health Care | 5 | 2018 | 240 | 0.660 |
Why?
|
| Sexual Behavior | 6 | 2019 | 320 | 0.660 |
Why?
|
| Psychotherapy | 1 | 2019 | 2 | 0.650 |
Why?
|
| Needs Assessment | 1 | 2019 | 29 | 0.650 |
Why?
|
| Organophosphates | 2 | 2019 | 9 | 0.650 |
Why?
|
| Central Nervous System Stimulants | 3 | 2016 | 4 | 0.650 |
Why?
|
| Child | 22 | 2021 | 2242 | 0.640 |
Why?
|
| Young Adult | 23 | 2021 | 2498 | 0.640 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 48 | 0.640 |
Why?
|
| Follow-Up Studies | 16 | 2021 | 370 | 0.640 |
Why?
|
| Rural Health Services | 1 | 2019 | 48 | 0.630 |
Why?
|
| Blood-Brain Barrier | 1 | 2019 | 24 | 0.630 |
Why?
|
| Adenine | 2 | 2019 | 91 | 0.620 |
Why?
|
| Hypertension | 3 | 2019 | 419 | 0.600 |
Why?
|
| Homosexuality, Male | 7 | 2022 | 52 | 0.580 |
Why?
|
| Alcoholism | 1 | 2017 | 17 | 0.570 |
Why?
|
| Cystatin C | 1 | 2017 | 9 | 0.560 |
Why?
|
| Tuberculosis, Pulmonary | 4 | 2017 | 324 | 0.550 |
Why?
|
| South Africa | 26 | 2021 | 7596 | 0.540 |
Why?
|
| Developing Countries | 6 | 2021 | 400 | 0.540 |
Why?
|
| Treatment Outcome | 12 | 2021 | 889 | 0.530 |
Why?
|
| Picornaviridae Infections | 3 | 2021 | 18 | 0.520 |
Why?
|
| Immunoconjugates | 1 | 2015 | 1 | 0.520 |
Why?
|
| Antipsychotic Agents | 2 | 2012 | 10 | 0.520 |
Why?
|
| HIV | 4 | 2018 | 380 | 0.510 |
Why?
|
| Retrospective Studies | 16 | 2021 | 799 | 0.510 |
Why?
|
| Pharmaceutical Preparations | 1 | 2015 | 44 | 0.500 |
Why?
|
| Mental Recall | 1 | 2015 | 3 | 0.500 |
Why?
|
| Pain | 1 | 2015 | 41 | 0.490 |
Why?
|
| Craniosynostoses | 1 | 2015 | 1 | 0.490 |
Why?
|
| Blood Loss, Surgical | 1 | 2015 | 5 | 0.490 |
Why?
|
| Tuberculosis | 5 | 2014 | 543 | 0.480 |
Why?
|
| Blood Transfusion | 1 | 2015 | 13 | 0.480 |
Why?
|
| Antitubercular Agents | 6 | 2022 | 322 | 0.480 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 142 | 0.470 |
Why?
|
| Vaccination | 5 | 2021 | 365 | 0.470 |
Why?
|
| Pneumonia, Viral | 3 | 2021 | 104 | 0.470 |
Why?
|
| Child Development | 1 | 2015 | 93 | 0.450 |
Why?
|
| Infant, Newborn | 11 | 2021 | 1479 | 0.440 |
Why?
|
| Activities of Daily Living | 7 | 2017 | 41 | 0.440 |
Why?
|
| Incidence | 14 | 2021 | 685 | 0.420 |
Why?
|
| Nasopharynx | 4 | 2021 | 151 | 0.420 |
Why?
|
| Respiratory System | 1 | 2012 | 9 | 0.410 |
Why?
|
| Health Status Indicators | 2 | 2020 | 17 | 0.400 |
Why?
|
| Child Health | 3 | 2021 | 77 | 0.400 |
Why?
|
| Cognition | 5 | 2022 | 75 | 0.400 |
Why?
|
| Rhinovirus | 3 | 2021 | 23 | 0.390 |
Why?
|
| Virus Diseases | 1 | 2012 | 55 | 0.390 |
Why?
|
| Pancreatitis, Chronic | 2 | 2021 | 4 | 0.390 |
Why?
|
| Patient Acuity | 2 | 2021 | 18 | 0.380 |
Why?
|
| Exercise | 4 | 2019 | 205 | 0.380 |
Why?
|
| Bayes Theorem | 2 | 2021 | 81 | 0.370 |
Why?
|
| Amyloid beta-Peptides | 4 | 2019 | 22 | 0.370 |
Why?
|
| Transgender Persons | 3 | 2019 | 24 | 0.360 |
Why?
|
| California | 6 | 2017 | 9 | 0.360 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2021 | 5 | 0.350 |
Why?
|
| Surveys and Questionnaires | 9 | 2021 | 563 | 0.350 |
Why?
|
| Depressive Disorder | 2 | 2020 | 10 | 0.340 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2010 | 100 | 0.340 |
Why?
|
| Genotype | 5 | 2019 | 442 | 0.330 |
Why?
|
| Feasibility Studies | 4 | 2019 | 101 | 0.330 |
Why?
|
| Community-Acquired Infections | 1 | 2010 | 102 | 0.330 |
Why?
|
| Risk-Taking | 4 | 2019 | 121 | 0.330 |
Why?
|
| Prospective Studies | 13 | 2021 | 1160 | 0.330 |
Why?
|
| Uveitis | 2 | 2019 | 5 | 0.330 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2020 | 27 | 0.320 |
Why?
|
| Gastroesophageal Reflux | 2 | 2021 | 3 | 0.320 |
Why?
|
| Metabolic Syndrome | 2 | 2020 | 64 | 0.320 |
Why?
|
| Secondary Prevention | 2 | 2022 | 20 | 0.320 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 112 | 0.310 |
Why?
|
| Focus Groups | 3 | 2020 | 196 | 0.310 |
Why?
|
| Proteins | 2 | 2019 | 20 | 0.300 |
Why?
|
| Uganda | 12 | 2016 | 197 | 0.300 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2014 | 187 | 0.300 |
Why?
|
| Sexual and Gender Minorities | 2 | 2019 | 29 | 0.300 |
Why?
|
| Primary Prevention | 2 | 2019 | 27 | 0.300 |
Why?
|
| Infant Mortality | 2 | 2010 | 97 | 0.290 |
Why?
|
| Unsafe Sex | 2 | 2019 | 46 | 0.290 |
Why?
|
| Vaccines, Conjugate | 3 | 2019 | 171 | 0.280 |
Why?
|
| Sustained Virologic Response | 2 | 2017 | 22 | 0.280 |
Why?
|
| Biomarkers | 5 | 2022 | 327 | 0.280 |
Why?
|
| Mass Screening | 4 | 2018 | 245 | 0.280 |
Why?
|
| RNA, Viral | 6 | 2020 | 303 | 0.260 |
Why?
|
| Mobile Applications | 2 | 2016 | 12 | 0.260 |
Why?
|
| Sexual Partners | 5 | 2019 | 215 | 0.250 |
Why?
|
| Cardiovascular Agents | 2 | 2016 | 11 | 0.250 |
Why?
|
| Pneumonia, Bacterial | 2 | 2016 | 54 | 0.250 |
Why?
|
| Coronary Disease | 2 | 2016 | 17 | 0.250 |
Why?
|
| Social Support | 2 | 2018 | 77 | 0.250 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 256 | 0.250 |
Why?
|
| Veterans | 2 | 2016 | 2 | 0.250 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 171 | 0.250 |
Why?
|
| Memory | 3 | 2021 | 3 | 0.240 |
Why?
|
| Graft Survival | 2 | 2021 | 40 | 0.240 |
Why?
|
| Cause of Death | 2 | 2017 | 221 | 0.230 |
Why?
|
| Socioeconomic Factors | 7 | 2015 | 411 | 0.230 |
Why?
|
| Alcohol Drinking | 2 | 2017 | 55 | 0.220 |
Why?
|
| Depressive Disorder, Major | 2 | 2022 | 20 | 0.220 |
Why?
|
| African Americans | 2 | 2020 | 47 | 0.220 |
Why?
|
| Predictive Value of Tests | 4 | 2018 | 188 | 0.210 |
Why?
|
| Visual Acuity | 2 | 2021 | 4 | 0.210 |
Why?
|
| Diagnosis, Differential | 2 | 2021 | 63 | 0.210 |
Why?
|
| Severity of Illness Index | 5 | 2019 | 253 | 0.210 |
Why?
|
| Neopterin | 1 | 2022 | 4 | 0.200 |
Why?
|
| Risk Assessment | 4 | 2016 | 225 | 0.200 |
Why?
|
| Syphilis | 1 | 2022 | 14 | 0.200 |
Why?
|
| Cerebral Amyloid Angiopathy | 2 | 2019 | 2 | 0.200 |
Why?
|
| Recurrence | 1 | 2022 | 29 | 0.200 |
Why?
|
| Frail Elderly | 1 | 2021 | 15 | 0.200 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 3 | 2012 | 19 | 0.200 |
Why?
|
| Trypsin | 1 | 2021 | 2 | 0.190 |
Why?
|
| Pancreatectomy | 1 | 2021 | 2 | 0.190 |
Why?
|
| Graft Rejection | 1 | 2021 | 15 | 0.190 |
Why?
|
| Serogroup | 3 | 2017 | 150 | 0.190 |
Why?
|
| Tenofovir | 2 | 2021 | 171 | 0.190 |
Why?
|
| Anxiety Disorders | 1 | 2021 | 15 | 0.190 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 42 | 0.190 |
Why?
|
| Coronavirus | 1 | 2021 | 14 | 0.190 |
Why?
|
| Cerebral Cortex | 2 | 2015 | 9 | 0.190 |
Why?
|
| Uveitis, Posterior | 1 | 2021 | 1 | 0.190 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2018 | 37 | 0.190 |
Why?
|
| Endpoint Determination | 1 | 2021 | 8 | 0.190 |
Why?
|
| Air Pollution | 1 | 2021 | 2 | 0.180 |
Why?
|
| Qualitative Research | 2 | 2020 | 321 | 0.180 |
Why?
|
| Anxiety | 1 | 2021 | 40 | 0.180 |
Why?
|
| Animals | 2 | 2015 | 1081 | 0.180 |
Why?
|
| Biomedical Technology | 1 | 2021 | 10 | 0.180 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 103 | 0.180 |
Why?
|
| Life Expectancy | 2 | 2019 | 31 | 0.180 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2018 | 33 | 0.180 |
Why?
|
| Air Pollution, Indoor | 1 | 2021 | 13 | 0.180 |
Why?
|
| Reoperation | 1 | 2020 | 8 | 0.180 |
Why?
|
| Genome, Bacterial | 2 | 2018 | 32 | 0.180 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2020 | 3 | 0.180 |
Why?
|
| Hand Strength | 1 | 2020 | 7 | 0.180 |
Why?
|
| Impulsive Behavior | 1 | 2020 | 2 | 0.180 |
Why?
|
| Apathy | 1 | 2020 | 2 | 0.180 |
Why?
|
| Healthy Aging | 1 | 2020 | 6 | 0.180 |
Why?
|
| Motor Skills | 1 | 2020 | 6 | 0.180 |
Why?
|
| Minority Groups | 1 | 2020 | 4 | 0.180 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 96 | 0.180 |
Why?
|
| Sentinel Surveillance | 2 | 2019 | 115 | 0.180 |
Why?
|
| Age Distribution | 1 | 2020 | 107 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2021 | 146 | 0.170 |
Why?
|
| Genetic Variation | 3 | 2019 | 175 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2021 | 71 | 0.170 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 4 | 0.170 |
Why?
|
| Cell Phone | 1 | 2020 | 34 | 0.170 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2013 | 158 | 0.170 |
Why?
|
| Uveitis, Anterior | 1 | 2019 | 1 | 0.170 |
Why?
|
| Rural Health | 3 | 2016 | 118 | 0.170 |
Why?
|
| Plaque, Amyloid | 1 | 2019 | 1 | 0.170 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2019 | 3 | 0.170 |
Why?
|
| Radiography, Thoracic | 1 | 2020 | 19 | 0.170 |
Why?
|
| Aqueous Humor | 1 | 2019 | 5 | 0.170 |
Why?
|
| Liver Transplantation | 1 | 2020 | 55 | 0.170 |
Why?
|
| Mutation | 5 | 2021 | 306 | 0.170 |
Why?
|
| Photometry | 1 | 2019 | 1 | 0.170 |
Why?
|
| Tomography, Optical Coherence | 1 | 2019 | 3 | 0.170 |
Why?
|
| Anterior Chamber | 1 | 2019 | 4 | 0.170 |
Why?
|
| Congresses as Topic | 1 | 2019 | 20 | 0.170 |
Why?
|
| Viremia | 1 | 2020 | 66 | 0.170 |
Why?
|
| Islands | 1 | 2019 | 2 | 0.170 |
Why?
|
| Lakes | 1 | 2019 | 3 | 0.170 |
Why?
|
| Peru | 1 | 2019 | 8 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 139 | 0.170 |
Why?
|
| Menopause | 1 | 2019 | 24 | 0.160 |
Why?
|
| Rubella Syndrome, Congenital | 1 | 2019 | 5 | 0.160 |
Why?
|
| World Health Organization | 1 | 2020 | 137 | 0.160 |
Why?
|
| Altitude | 1 | 2019 | 9 | 0.160 |
Why?
|
| Macular Edema | 1 | 2019 | 1 | 0.160 |
Why?
|
| Caregivers | 2 | 2021 | 76 | 0.160 |
Why?
|
| Life Style | 2 | 2018 | 86 | 0.160 |
Why?
|
| Cerebrospinal Fluid | 2 | 2017 | 5 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 17 | 0.160 |
Why?
|
| Neurofibrillary Tangles | 1 | 2019 | 1 | 0.160 |
Why?
|
| tau Proteins | 1 | 2019 | 7 | 0.160 |
Why?
|
| Atrophy | 1 | 2019 | 6 | 0.160 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 40 | 0.160 |
Why?
|
| Glucocorticoids | 1 | 2019 | 20 | 0.160 |
Why?
|
| Research | 1 | 2019 | 65 | 0.160 |
Why?
|
| Neurons | 1 | 2019 | 23 | 0.160 |
Why?
|
| Psychology | 1 | 2018 | 4 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 22 | 0.160 |
Why?
|
| Endemic Diseases | 1 | 2018 | 15 | 0.160 |
Why?
|
| Bacterial Infections | 1 | 2019 | 54 | 0.160 |
Why?
|
| Carrier State | 1 | 2019 | 92 | 0.160 |
Why?
|
| Autopsy | 2 | 2019 | 140 | 0.160 |
Why?
|
| Population Surveillance | 2 | 2021 | 325 | 0.160 |
Why?
|
| Europe | 5 | 2017 | 56 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 2 | 2016 | 260 | 0.150 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 16 | 0.150 |
Why?
|
| Apolipoprotein E4 | 2 | 2021 | 4 | 0.150 |
Why?
|
| Bacteremia | 2 | 2017 | 79 | 0.150 |
Why?
|
| Time Factors | 6 | 2018 | 507 | 0.150 |
Why?
|
| Quality of Health Care | 1 | 2018 | 62 | 0.150 |
Why?
|
| Ambulatory Care | 1 | 2018 | 54 | 0.150 |
Why?
|
| Health Services Research | 1 | 2018 | 58 | 0.150 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2018 | 20 | 0.150 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2017 | 3 | 0.140 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 7 | 0.140 |
Why?
|
| Blood Coagulation Disorders | 1 | 2017 | 6 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 176 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 34 | 0.140 |
Why?
|
| Chagas Disease | 1 | 2017 | 1 | 0.140 |
Why?
|
| Health Risk Behaviors | 1 | 2017 | 7 | 0.140 |
Why?
|
| Emigrants and Immigrants | 1 | 2017 | 11 | 0.140 |
Why?
|
| Vascular Remodeling | 1 | 2017 | 1 | 0.140 |
Why?
|
| Proportional Hazards Models | 4 | 2021 | 163 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2017 | 26 | 0.140 |
Why?
|
| Australia | 3 | 2021 | 48 | 0.140 |
Why?
|
| Benzoxazines | 2 | 2015 | 123 | 0.140 |
Why?
|
| Ecological Momentary Assessment | 1 | 2016 | 1 | 0.140 |
Why?
|
| Medical Informatics Applications | 1 | 2016 | 1 | 0.140 |
Why?
|
| Antibodies, Viral | 1 | 2019 | 284 | 0.140 |
Why?
|
| Health Education | 1 | 2017 | 35 | 0.140 |
Why?
|
| Terminally Ill | 1 | 2017 | 21 | 0.140 |
Why?
|
| Alleles | 2 | 2016 | 143 | 0.140 |
Why?
|
| United States | 3 | 2021 | 132 | 0.140 |
Why?
|
| Sex Workers | 1 | 2018 | 116 | 0.140 |
Why?
|
| Gastrostomy | 1 | 2016 | 1 | 0.140 |
Why?
|
| Fundoplication | 1 | 2016 | 1 | 0.140 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2017 | 103 | 0.140 |
Why?
|
| DNA Repeat Expansion | 1 | 2016 | 1 | 0.130 |
Why?
|
| Attitude to Health | 1 | 2016 | 56 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2016 | 34 | 0.130 |
Why?
|
| Survival Analysis | 3 | 2012 | 149 | 0.130 |
Why?
|
| Biomedical Research | 1 | 2017 | 49 | 0.130 |
Why?
|
| Vascular Stiffness | 1 | 2017 | 41 | 0.130 |
Why?
|
| Awareness | 2 | 2015 | 18 | 0.130 |
Why?
|
| Forecasting | 1 | 2016 | 20 | 0.130 |
Why?
|
| Multigene Family | 1 | 2016 | 6 | 0.130 |
Why?
|
| Virus Replication | 1 | 2017 | 88 | 0.130 |
Why?
|
| Disease Progression | 3 | 2019 | 154 | 0.130 |
Why?
|
| South Australia | 3 | 2021 | 3 | 0.130 |
Why?
|
| Mitochondria | 1 | 2016 | 12 | 0.130 |
Why?
|
| Genes, Bacterial | 1 | 2016 | 23 | 0.130 |
Why?
|
| Recombination, Genetic | 1 | 2016 | 27 | 0.130 |
Why?
|
| Drug Industry | 1 | 2015 | 5 | 0.130 |
Why?
|
| Ataxia | 1 | 2015 | 4 | 0.130 |
Why?
|
| Mental Disorders | 2 | 2013 | 44 | 0.130 |
Why?
|
| Bisexuality | 1 | 2015 | 3 | 0.130 |
Why?
|
| HIV Protease Inhibitors | 2 | 2014 | 92 | 0.130 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 10 | 0.130 |
Why?
|
| Odds Ratio | 5 | 2017 | 133 | 0.120 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 26 | 0.120 |
Why?
|
| Schizophrenic Psychology | 1 | 2015 | 2 | 0.120 |
Why?
|
| Schizophrenia | 1 | 2015 | 4 | 0.120 |
Why?
|
| Cardiology | 1 | 2015 | 1 | 0.120 |
Why?
|
| Psychomotor Performance | 1 | 2015 | 12 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 2 | 0.120 |
Why?
|
| Synaptophysin | 1 | 2015 | 3 | 0.120 |
Why?
|
| Contact Tracing | 1 | 2015 | 48 | 0.120 |
Why?
|
| Hematologic Agents | 1 | 2015 | 2 | 0.120 |
Why?
|
| Postoperative Hemorrhage | 1 | 2015 | 2 | 0.120 |
Why?
|
| Perioperative Care | 1 | 2015 | 8 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2015 | 26 | 0.120 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 39 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 198 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 43 | 0.120 |
Why?
|
| Meningitis, Bacterial | 1 | 2015 | 38 | 0.120 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2014 | 1 | 0.120 |
Why?
|
| Calcitriol | 1 | 2014 | 6 | 0.120 |
Why?
|
| Dermatologic Agents | 1 | 2014 | 6 | 0.110 |
Why?
|
| Zinc Sulfate | 1 | 2014 | 6 | 0.110 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2014 | 14 | 0.110 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 529 | 0.110 |
Why?
|
| Tuberculin Test | 1 | 2014 | 49 | 0.110 |
Why?
|
| Smoking | 2 | 2015 | 100 | 0.110 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2014 | 151 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2013 | 1 | 0.110 |
Why?
|
| Research Design | 3 | 2021 | 124 | 0.110 |
Why?
|
| Encephalitis | 1 | 2013 | 2 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 3 | 2019 | 181 | 0.110 |
Why?
|
| Phylogeny | 3 | 2019 | 231 | 0.110 |
Why?
|
| Interview, Psychological | 1 | 2012 | 6 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 244 | 0.100 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 6 | 0.100 |
Why?
|
| Hippocampus | 2 | 2017 | 2 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 45 | 0.100 |
Why?
|
| Memory Disorders | 1 | 2012 | 4 | 0.100 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2012 | 1 | 0.100 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2012 | 1 | 0.100 |
Why?
|
| Orthomyxoviridae | 1 | 2012 | 33 | 0.100 |
Why?
|
| Unemployment | 1 | 2012 | 10 | 0.100 |
Why?
|
| Adenoviridae | 1 | 2012 | 39 | 0.100 |
Why?
|
| Rural Population | 3 | 2016 | 654 | 0.100 |
Why?
|
| British Columbia | 3 | 2017 | 4 | 0.100 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2012 | 7 | 0.100 |
Why?
|
| Mice | 1 | 2012 | 135 | 0.100 |
Why?
|
| Chemoprevention | 1 | 2012 | 33 | 0.100 |
Why?
|
| Attention | 1 | 2011 | 5 | 0.100 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2011 | 10 | 0.100 |
Why?
|
| Learning | 1 | 2011 | 12 | 0.100 |
Why?
|
| Anti-Infective Agents | 2 | 2010 | 57 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 106 | 0.090 |
Why?
|
| Latin America | 2 | 2017 | 10 | 0.090 |
Why?
|
| Liver Diseases | 2 | 2021 | 18 | 0.090 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2008 | 118 | 0.090 |
Why?
|
| Linear Models | 1 | 2010 | 83 | 0.090 |
Why?
|
| Hospitals | 2 | 2021 | 103 | 0.090 |
Why?
|
| Influenza, Human | 1 | 2014 | 374 | 0.080 |
Why?
|
| Malaria | 1 | 2012 | 213 | 0.080 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 217 | 0.080 |
Why?
|
| Educational Status | 2 | 2013 | 68 | 0.080 |
Why?
|
| Hematologic Diseases | 1 | 2009 | 4 | 0.080 |
Why?
|
| Family Characteristics | 3 | 2016 | 135 | 0.080 |
Why?
|
| Sex Factors | 3 | 2018 | 227 | 0.080 |
Why?
|
| Breast Feeding | 1 | 2010 | 120 | 0.080 |
Why?
|
| Zidovudine | 1 | 2009 | 59 | 0.080 |
Why?
|
| Reproduction | 1 | 2009 | 25 | 0.080 |
Why?
|
| Smartphone | 2 | 2020 | 4 | 0.080 |
Why?
|
| HIV Antibodies | 1 | 2011 | 247 | 0.080 |
Why?
|
| Intestine, Small | 1 | 2008 | 4 | 0.080 |
Why?
|
| Intestinal Mucosa | 1 | 2008 | 9 | 0.080 |
Why?
|
| Stavudine | 1 | 2009 | 78 | 0.080 |
Why?
|
| Liver | 1 | 2008 | 74 | 0.080 |
Why?
|
| Women | 2 | 2009 | 12 | 0.080 |
Why?
|
| Child, Orphaned | 1 | 2008 | 16 | 0.070 |
Why?
|
| Lipids | 1 | 2008 | 81 | 0.070 |
Why?
|
| Seasons | 2 | 2021 | 154 | 0.070 |
Why?
|
| Diet | 2 | 2021 | 109 | 0.070 |
Why?
|
| Safe Sex | 2 | 2018 | 68 | 0.070 |
Why?
|
| Pregnancy | 3 | 2021 | 1862 | 0.070 |
Why?
|
| Registries | 2 | 2020 | 91 | 0.070 |
Why?
|
| DNA, Bacterial | 2 | 2018 | 53 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2019 | 133 | 0.070 |
Why?
|
| Putamen | 1 | 2006 | 1 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2006 | 3 | 0.070 |
Why?
|
| Plasma | 2 | 2017 | 39 | 0.070 |
Why?
|
| Health Status | 2 | 2019 | 111 | 0.070 |
Why?
|
| Psychometrics | 1 | 2006 | 22 | 0.070 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2010 | 472 | 0.060 |
Why?
|
| ROC Curve | 2 | 2016 | 51 | 0.060 |
Why?
|
| Cholesterol, HDL | 2 | 2020 | 32 | 0.060 |
Why?
|
| Self Report | 2 | 2019 | 114 | 0.060 |
Why?
|
| Triglycerides | 2 | 2020 | 47 | 0.060 |
Why?
|
| Risk | 2 | 2020 | 87 | 0.060 |
Why?
|
| Amyloidosis | 1 | 2005 | 3 | 0.060 |
Why?
|
| Canada | 2 | 2015 | 11 | 0.060 |
Why?
|
| Brain Diseases | 1 | 2005 | 24 | 0.060 |
Why?
|
| Caribbean Region | 1 | 2003 | 11 | 0.060 |
Why?
|
| Water Supply | 1 | 2003 | 10 | 0.060 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 2003 | 17 | 0.060 |
Why?
|
| United Kingdom | 2 | 2013 | 33 | 0.050 |
Why?
|
| Fluid Therapy | 1 | 2003 | 25 | 0.050 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2003 | 28 | 0.050 |
Why?
|
| Memory, Short-Term | 2 | 2013 | 7 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2013 | 5 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2017 | 253 | 0.050 |
Why?
|
| Hepatitis C | 2 | 2014 | 37 | 0.050 |
Why?
|
| Alkynes | 2 | 2015 | 117 | 0.050 |
Why?
|
| Cyclopropanes | 2 | 2015 | 123 | 0.050 |
Why?
|
| Fatigue | 1 | 2022 | 20 | 0.050 |
Why?
|
| Drug Resistance, Viral | 2 | 2014 | 278 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 10 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2021 | 1 | 0.050 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2021 | 2 | 0.050 |
Why?
|
| Prognosis | 2 | 2016 | 199 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2012 | 15 | 0.050 |
Why?
|
| Respiratory Sounds | 1 | 2021 | 10 | 0.050 |
Why?
|
| Health Status Disparities | 1 | 2021 | 35 | 0.050 |
Why?
|
| Multimorbidity | 1 | 2021 | 42 | 0.050 |
Why?
|
| Emtricitabine | 1 | 2021 | 78 | 0.050 |
Why?
|
| Proton Pump Inhibitors | 1 | 2021 | 2 | 0.050 |
Why?
|
| Asia | 1 | 2021 | 72 | 0.050 |
Why?
|
| Ophthalmologists | 1 | 2021 | 1 | 0.050 |
Why?
|
| Zambia | 1 | 2021 | 115 | 0.050 |
Why?
|
| Patients | 1 | 2021 | 3 | 0.050 |
Why?
|
| Biomass | 1 | 2021 | 2 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 37 | 0.050 |
Why?
|
| Cooking | 1 | 2021 | 7 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2021 | 30 | 0.050 |
Why?
|
| New Zealand | 1 | 2020 | 8 | 0.050 |
Why?
|
| Consensus | 1 | 2021 | 62 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2020 | 8 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2020 | 17 | 0.040 |
Why?
|
| Harm Reduction | 1 | 2020 | 7 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 2020 | 2 | 0.040 |
Why?
|
| Africa | 1 | 2021 | 376 | 0.040 |
Why?
|
| Substance Abuse, Intravenous | 2 | 2012 | 11 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2019 | 10 | 0.040 |
Why?
|
| Employment | 2 | 2013 | 27 | 0.040 |
Why?
|
| 5' Untranslated Regions | 1 | 2019 | 7 | 0.040 |
Why?
|
| Cell Count | 1 | 2019 | 10 | 0.040 |
Why?
|
| Motor Activity | 2 | 2013 | 46 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 47 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 231 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 38 | 0.040 |
Why?
|
| Rubella virus | 1 | 2019 | 8 | 0.040 |
Why?
|
| Medical Records | 1 | 2019 | 23 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 279 | 0.040 |
Why?
|
| Directive Counseling | 1 | 2019 | 15 | 0.040 |
Why?
|
| Health Surveys | 1 | 2019 | 59 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2019 | 107 | 0.040 |
Why?
|
| Darunavir | 1 | 2018 | 12 | 0.040 |
Why?
|
| Mexico | 1 | 2018 | 3 | 0.040 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 69 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 156 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2019 | 80 | 0.040 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2018 | 1 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2019 | 353 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 266 | 0.040 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2018 | 21 | 0.040 |
Why?
|
| Ritonavir | 1 | 2018 | 137 | 0.040 |
Why?
|
| Geography | 1 | 2018 | 60 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2017 | 21 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2017 | 29 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 42 | 0.040 |
Why?
|
| Antiprotozoal Agents | 1 | 2017 | 7 | 0.040 |
Why?
|
| Angiopoietin-2 | 1 | 2017 | 1 | 0.040 |
Why?
|
| Receptor, TIE-2 | 1 | 2017 | 1 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2017 | 38 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 14 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2018 | 198 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 106 | 0.030 |
Why?
|
| Immunization, Secondary | 1 | 2017 | 72 | 0.030 |
Why?
|
| Heterosexuality | 1 | 2016 | 30 | 0.030 |
Why?
|
| Mosaicism | 1 | 2016 | 1 | 0.030 |
Why?
|
| C9orf72 Protein | 1 | 2016 | 2 | 0.030 |
Why?
|
| Scotland | 1 | 2016 | 5 | 0.030 |
Why?
|
| Artifacts | 1 | 2016 | 3 | 0.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2016 | 14 | 0.030 |
Why?
|
| DNA Primers | 1 | 2016 | 55 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 203 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 31 | 0.030 |
Why?
|
| Base Sequence | 1 | 2016 | 149 | 0.030 |
Why?
|
| Selection, Genetic | 1 | 2016 | 31 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 153 | 0.030 |
Why?
|
| Evolution, Molecular | 1 | 2016 | 60 | 0.030 |
Why?
|
| Patient Compliance | 2 | 2007 | 120 | 0.030 |
Why?
|
| Knowledge | 1 | 2015 | 2 | 0.030 |
Why?
|
| Child, Hospitalized | 1 | 2015 | 26 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 231 | 0.030 |
Why?
|
| Pakistan | 1 | 2015 | 2 | 0.030 |
Why?
|
| Genomics | 1 | 2016 | 109 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2015 | 31 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2015 | 9 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2015 | 30 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 385 | 0.030 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 43 | 0.030 |
Why?
|
| Cytokines | 1 | 2015 | 107 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2015 | 43 | 0.030 |
Why?
|
| Drug Users | 1 | 2014 | 3 | 0.030 |
Why?
|
| North America | 1 | 2014 | 11 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2014 | 31 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 18 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 127 | 0.030 |
Why?
|
| Affect | 1 | 2013 | 4 | 0.030 |
Why?
|
| Foot Joints | 1 | 2013 | 1 | 0.030 |
Why?
|
| Hand Joints | 1 | 2013 | 1 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2013 | 10 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 5 | 0.030 |
Why?
|
| Social Stigma | 1 | 2014 | 80 | 0.030 |
Why?
|
| Acute Disease | 1 | 2013 | 105 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2013 | 23 | 0.030 |
Why?
|
| Radiography | 1 | 2013 | 80 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 38 | 0.030 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2013 | 10 | 0.030 |
Why?
|
| Community Health Services | 1 | 2013 | 58 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2013 | 28 | 0.030 |
Why?
|
| Military Personnel | 1 | 2013 | 1 | 0.030 |
Why?
|
| Communicable Disease Control | 1 | 2014 | 101 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 77 | 0.030 |
Why?
|
| Transients and Migrants | 1 | 2013 | 39 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2013 | 111 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2013 | 82 | 0.030 |
Why?
|
| Verbal Learning | 1 | 2012 | 3 | 0.030 |
Why?
|
| Substance Abuse Detection | 1 | 2012 | 2 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2013 | 165 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2012 | 26 | 0.020 |
Why?
|
| Opioid-Related Disorders | 1 | 2011 | 1 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2011 | 34 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2011 | 22 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 76 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 37 | 0.020 |
Why?
|
| Mycobacterium | 1 | 2011 | 16 | 0.020 |
Why?
|
| Critical Illness | 1 | 2010 | 44 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 262 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2009 | 11 | 0.020 |
Why?
|
| Transaminases | 1 | 2008 | 5 | 0.020 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2008 | 12 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2008 | 1 | 0.020 |
Why?
|
| Home Care Services | 1 | 2008 | 15 | 0.020 |
Why?
|
| Cholesterol | 1 | 2008 | 38 | 0.020 |
Why?
|
| Mothers | 1 | 2010 | 195 | 0.020 |
Why?
|
| Survival Rate | 1 | 2008 | 96 | 0.020 |
Why?
|
| Child Mortality | 1 | 2008 | 96 | 0.020 |
Why?
|
| Nevirapine | 1 | 2008 | 146 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2008 | 150 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2005 | 2 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 237 | 0.010 |
Why?
|
| Neurologic Examination | 1 | 2004 | 5 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 45 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 64 | 0.010 |
Why?
|